CureVac

CureVac N.V. is a German biopharmaceutical company that creates therapies based on messenger RNA (mRNA). It is headquartered in Tübingen, Germany. The company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee.

CureVac had about 240 employees in November 2015.[1]

The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases.[2]

References
  1. "Gates, Hopp back $110M megaround for CureVac's mRNA work".
  2. Carroll, John (18 October 2017). "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines". endpts.com.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.